FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Antibiotic Therapy for Uncomplicated Acute Appendicitis: Ten-Year Follow-Up of the APPAC Randomized Clinical Trial. PMID 41563747 · JAMA · 2026-Mar-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study. PMID 41499759 · Blood Adv · 2026-Mar-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of Survey Item Wording and Response Options on Prevalence of Beliefs About Nicotine Causing Cancer: A Randomized Survey Experiment. PMID 41405956 · Nicotine Tob Res · 2026-Mar-24 The study is a randomized survey experiment examining how question wording affects public beliefs about nicotine causing cancer. It is not a therapeutic clinical trial in cancer patients, has no drug intervention, and does not report any time-to-event efficacy endpoint like overall survival or progression-free survival. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of NFL-101 as a Smoking Cessation Therapy: A Randomized Phase II Clinical Trial CESTO2. PMID 40884488 · Nicotine Tob Res · 2026-Mar-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| HSK21542 for Postoperative Analgesia in Gynecological Surgery: A Pooled Post-Hoc Analysis of Two Phase III Randomized Controlled Trials. PMID 41874970 · Anesth Analg · 2026-Mar-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications. PMID 41870800 · Curr Cardiol Rep · 2026-Mar-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Perfluorohexyloctane eye drops in treating dry eye disease associated with meibomian gland dysfunction: a post hoc analysis by baseline severity. PMID 41870723 · Int Ophthalmol · 2026-Mar-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of oral mucositis management based on MASCC/ISOO guidelines in pediatric oncology patients: a randomized controlled trial. PMID 41863643 · Support Care Cancer · 2026-Mar-21 The study is a randomized trial in oncology with original results, but it is not a Phase III/IIIb or Phase II/III trial, does not have a primary time-to-event efficacy endpoint, and the intervention is a non-drug oral care protocol. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. PMID 41765029 · Lancet · 2026-Mar-21 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| [Efficacy of Ganciclovir Combined With Recombinant Human Interferon α-1b for Viral Encephalitis in Children]. PMID 42021910 · Sichuan Da Xue Xue Bao Yi Xue Ban · 2026-Mar-20 The study is a randomized trial in humans with a drug intervention (ganciclovir + interferon), but it investigates viral encephalitis, not a malignant neoplasm (oncology). The primary efficacy endpoints are symptom recovery time, clinical efficacy rate, EEG abnormalities, and biomarkers, none of which are time-to-event endpoints like OS or PFS. Therefore, it is excluded on both oncology and endpoint grounds. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Therapy for Localized Pancreatic Cancer. PMID 41899612 · Cancers (Basel) · 2026-Mar-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non-muscle-invasive Bladder Cancer. PMID 41864769 · Eur Urol Oncol · 2026-Mar-20 The study is a randomized controlled trial for non-muscle-invasive bladder cancer reporting recurrence-free survival, which is a time-to-event endpoint. However, it does not meet the eligibility criteria because it is not a Phase III or Phase II/III trial (the phase is not specified as such in the abstract, and the deterministic review indicates it is not a phase 3 trial), and it does not involve a drug-containing intervention as defined for this cohort (the intervention is local chemoresection with mitomycin C, but this is a procedure-based/local therapy rather than a systemic drug intervention eligible for this specific cohort). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Reply to Roberto Contieri, Massimo Lazzeri, Sisto Perdonà, and Rodolfo Hurle's Letter to the Editor re: Kitamura, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008. PMID 41864759 · Eur Urol · 2026-Mar-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trial. PMID 41863008 · Trials · 2026-Mar-20 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Kin KeeperSM Breast and Cervical Cancer Prevention: An Educational Intervention: A Community-Based Randomized Controlled Trial in Black, Latina, and Arab Women. PMID 41860672 · J Cancer Educ · 2026-Mar-20 The study is a randomized oncology trial in humans with original results, but it lacks a drug intervention and a time-to-event efficacy endpoint. It is an educational prevention study, not a Phase III drug efficacy trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical efficacy and safety of anti-VEGF biosimilars compared to reference anti-VEGF agents for neovascular age-related macular degeneration: a systematic review, meta-analysis, and meta-regression. PMID 41860622 · Int Ophthalmol · 2026-Mar-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Testing interventions to increase participation in the Australian National Bowel Cancer Screening Program among persistent never-screeners: study protocol for a randomised controlled trial. PMID 41857651 · Trials · 2026-Mar-20 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| PROTECTOR / FIRE‑10: study protocol for a prospective, randomized, open-label, multicenter phase III trial to investigate the efficacy of preoperative systemic therapy in advanced colon cancer. PMID 41857556 · BMC Cancer · 2026-Mar-20 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness of first-line encorafenib plus cetuximab with mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer. PMID 41797900 · iScience · 2026-Mar-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study. PMID 41628308 · J Clin Oncol · 2026-Mar-20 The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and is an original result report. However, it is excluded because its primary endpoint is not a time-to-event efficacy endpoint; it reports pharmacodynamic changes (Ki67, ER) rather than OS, PFS, or similar survival outcomes with associated Kaplan-Meier or HR data. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial. PMID 41570275 · J Clin Oncol · 2026-Mar-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Low-concentration bimatoprost 0.01% and timolol 0.1% eye gel versus bimatoprost 0.03% and timolol 0.5% eye drops in open-angle glaucoma or ocular hypertension: a phase III randomised study. PMID 41093358 · Br J Ophthalmol · 2026-Mar-20 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14). PMID 41862335 · Eur Urol Oncol · 2026-Mar-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial. PMID 41857036 · Nat Commun · 2026-Mar-19 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of an early warning system on the outcome of patients with haematological malignancies receiving high-dose chemotherapy with or without haematopoietic cell transplantation: a protocol of the ALHERT cluster randomised trial. PMID 41856593 · BMJ Open · 2026-Mar-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-term protection of an inactivated enterovirus type 71 vaccine against hand, foot, and mouth diseases in children: a modelling study. PMID 41650673 · Vaccine · 2026-Mar-19 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Ivarmacitinib ointment in treatment of adults with mild-to-moderate atopic dermatitis: phase III of a randomized double-blind placebo-controlled phase II/III clinical trial. PMID 41317338 · Br J Dermatol · 2026-Mar-19 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cluster randomised controlled trial for service delivery redesign of primary care for people with diabetes: study protocol. PMID 41857847 · BMJ Open · 2026-Mar-18 方案论文未报告临床试验结果。 |
H
L
|
旧查询独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Superior efficacy and comparable safety of calcipotriol plus betamethasone dipropionate foam vs. ointment in Chinese patients with plaque psoriasis: A randomized phase 3 trial. PMID 41850772 · Chin Med J (Engl) · 2026-Mar-17 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Identification of tofersen PD-response biomarkers in VALOR clinical trial CSF via multiplexed quantitative proteomics. PMID 41850233 · Cell Rep Med · 2026-Mar-17 The study is a Phase III randomized trial of a drug (tofersen) in humans, but it is not an oncology study (ALS is a neurodegenerative disease). Furthermore, the primary analysis is a pharmacodynamic biomarker study (proteomics), not a time-to-event efficacy endpoint (OS, PFS, etc.) report. |
H
L
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Treatment guided by cerebral oximetry in newborns receiving invasive mechanical ventilation: study protocol for step one of the SafeBoosC-IIIv randomised clinical trial. PMID 41845443 · Trials · 2026-Mar-17 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| "Having surgery is necessary" - a qualitative analysis of the experiences of frail older adults treated with, and recovering from colorectal cancer surgery. PMID 41845272 · BMC Geriatr · 2026-Mar-17 This is a qualitative analysis of patient experiences from the control group of a randomized trial. It does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) and lacks a drug-containing intervention. The publication type is 'Journal Article' with 'Randomized Controlled Trial' but the content is qualitative, not a primary/secondary efficacy result. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of concurrent hyperbaric oxygen therapy with chemoradiotherapy for glioma: a meta-analysis. PMID 41843266 · Clin Transl Oncol · 2026-Mar-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Integrated psychological resilience and nutritional support improves sleep, emotional wellbeing, inflammation, and clinical recovery in colon cancer: a randomized controlled trial. PMID 41841224 · Psychol Health Med · 2026-Mar-17 The study is an oncology RCT with time-to-event endpoints, but it fails the drug intervention criterion (intervention is non-drug). The phase is also not definitively established as Phase III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial. PMID 41759531 · Cell Rep Med · 2026-Mar-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The effects of a smoking cessation intervention on mortality after a 32.5-year follow-up period: a randomized clinical trial. PMID 41164942 · Am J Epidemiol · 2026-Mar-17 Study is a randomized clinical trial with time-to-event mortality endpoints, but it is a smoking cessation intervention trial (non-drug) and does not provide evidence of being a Phase III/IIIb or Phase II/III oncology trial. The primary intervention is behavioral (smoking cessation program) with bronchodilator/placebo arms, but the drug component (bronchodilator) is not the primary intervention and the trial is not focused on a drug-containing oncology treatment. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men. PMID 41162330 · Clin Infect Dis · 2026-Mar-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment. PMID 41128642 · J Clin Endocrinol Metab · 2026-Mar-17 The study is a Phase III randomized trial of a drug for acromegaly, which is not a human malignant neoplasm. The primary efficacy endpoint is a biochemical response (IGF-I normalization), not a time-to-event endpoint like OS, PFS, or DFS, and there is no indication of Kaplan-Meier analysis or hazard ratios for survival/time-to-event data. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among Women Living with HIV in South Africa: Primary Outcomes from the ACT 2 Randomized Trial. PMID 41891028 · medRxiv · 2026-Mar-16 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer. PMID 41528981 · Clin Cancer Res · 2026-Mar-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Valued Living intervention to increase advance care planning and well-being in depressed and anxious adults with advanced cancer: Randomized trial in community oncology clinics. PMID 41848105 · Cancer · 2026-Mar-15 The study is a randomized trial in oncology patients but fails key eligibility criteria: it is not explicitly a Phase III trial, lacks a time-to-event primary efficacy endpoint (OS/PFS/etc.), and does not involve a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Eligibility criteria in phase 3 randomized controlled trials in metastatic non-small cell lung cancer. PMID 41838447 · Cancer · 2026-Mar-15 This is a meta-analysis of eligibility criteria across multiple phase 3 RCTs, not an original report of a single trial's efficacy results. It lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as required. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer. PMID 41817106 · Cancer · 2026-Mar-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy. PMID 41808570 · Cancer · 2026-Mar-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Bowel Cleansing with Mini S-Oral Sulfate Tablet versus the Conventional Oral Sulfate Tablet: A Prospective, Randomized, Investigator-Blinded, Multicenter, Noninferior, Phase 3 Trial. PMID 41306094 · Gut Liver · 2026-Mar-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Parotid-Sparing Versus Conventional Whole Brain Radiation Therapy: A Multi-Institutional Randomized Clinical Trial. PMID 41161645 · Int J Radiat Oncol Biol Phys · 2026-Mar-15 The study is a randomized trial in oncology with original results, but it does not meet all required criteria: it lacks a drug-containing intervention (it compares radiotherapy techniques), it has no time-to-event efficacy endpoint (the primary endpoint is xerostomia score), and the phase is not explicitly stated as Phase III/IIIb or II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated Dose Escalation Versus Conventionally Fractionated Radiation Therapy for Patients With Intermediate- and High-Risk Localized Prostate Cancer: Long-Term Results of the HYPRO Trial. PMID 41106690 · Int J Radiat Oncol Biol Phys · 2026-Mar-15 The report is an original Phase III randomized trial in oncology with human patients and time-to-event endpoints (relapse-free survival, overall survival). However, the intervention is radiation therapy, not a drug-containing intervention. Therefore, it does not meet the criterion of having a drug-containing intervention. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| HEBERSaVax immunotherapy combined with first-line chemotherapy in advanced ovarian cancer: Phase II CENTAURO-4 trial results. PMID 41099583 · Int J Cancer · 2026-Mar-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| [Comparison of the efficacy and safety of venetoclax plus azacitidine versus D-CAG regimen in the treatment of elderly patients with relapsed or refractory acute myeloid leukemia]. PMID 41991313 · Zhonghua Xue Ye Xue Za Zhi · 2026-Mar-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study. PMID 41830344 · Clin Infect Dis · 2026-Mar-14 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |